Stocksigma LogoStocksigma Logo

NCLT Initiates CIRP Against Shilpa Medicare Subsidiary FTF Pharma Over ₹2.18 Crore Dues

NCLT Ahmedabad Bench admitted a Section 9 IBC petition filed by Immacule Lifesciences against FTF Pharma, a wholly owned subsidiary of Shilpa Medicare

NCLT Initiates CIRP Against Shilpa Medicare Subsidiary FTF Pharma Over ₹2.18 Crore Dues

Shilpa Medicare Ltd · Others (Uncategorized) · 10 Sept 2026, 8:29 pm

NCLT Initiates CIRP Against Shilpa Medicare Subsidiary FTF Pharma Over ₹2.18 Crore Dues NCLT Ahmedabad Bench admitted a Section 9 IBC petition filed by Immacule Lifesciences against FTF Pharma, a wholly owned subsidiary of Shilpa Medicare, ordering Corporate Insolvency Resolution Process (CIRP) commencement on 9th Sep'26. The proceedings involve an outstanding operational debt of ₹2.18 Cr under a technology transfer agreement. NCLT imposed a statutory moratorium and appointed Sunil Kumar Kedia as Interim Resolution Professional. Shilpa Medicare stated no contravention was found against the listed entity, financial impact remains presently unascertainable, and it is consulting legal advisors.

Original exchange filing (PDF)

More announcements from Shilpa Medicare Ltd

All Shilpa Medicare Ltd announcements